IP Library › Granted Patent US 12,448,635

Granted Patent B2

US 12,448,635 · App. 17/057,140 · Granted Oct 21, 2025

Polynucleotide synthesis method, system and kit

Inventors: John Milton (Oxford, GB); Sobia Nayyar (Cambridge, GB); Jan Riedl (Cambridge, GB); Ryosuke Ogaki (Cambridge, GB)

Assignee: Oxford Nanopore Technologies PLC

C12P19/34 C12N15/1068 C12Q1/6806 C12Q1/6855

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,448,635
App. No.: 17/057,140
Granted: Oct 21, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention relates to new methods for synthesising polynucleotide molecules according to a predefined nucleotide sequence. The invention also relates to methods for the assembly of synthetic polynucleotides following synthesis, as well as systems and kits for performing the synthesis and/or assembly methods.

Claims (119)

1. A method of synthesising a double-stranded polynucleotide having a predefined sequence in vitro, the method comprising performing cycles of synthesis,

wherein each cycle of synthesis comprises:

(1) providing a double-stranded scaffold polynucleotide comprising a synthesis strand and a support strand hybridized thereto, wherein the synthesis strand comprises a primer strand portion, and the support strand comprises a universal nucleotide;

(2) cleaving the double-stranded scaffold polynucleotide at a cleavage site defined by a sequence comprising the universal nucleotide in the support strand, and removing the universal nucleotide from the scaffold polynucleotide to provide a cleaved double-stranded scaffold polynucleotide;

(3) extending the cleaved double-stranded scaffold polynucleotide with a nucleotide of the predefined sequence by action of a nucleotide transferase or polymerase enzyme, the nucleotide comprising a reversible terminator group which prevents further extension by the nucleotide transferase or polymerase enzyme;

(4) removing the reversible terminator group from the nucleotide of the predefined sequence; and

(5) ligating a double-stranded ligation polynucleotide to the cleaved double-stranded scaffold polynucleotide, the double-stranded ligation polynucleotide comprising a support strand comprising a partner nucleotide for the nucleotide of the predefined sequence and a universal nucleotide which defines a cleavage site for a subsequent cycle,

wherein upon ligation of the support strand, the nucleotide of the predefined sequence pairs with the partner nucleotide.

2. The method according to claim 1 , wherein

step (1) comprises providing a double-stranded scaffold polynucleotide comprising a synthesis strand end a support strand hybridized thereto, wherein the synthesis strand comprises a primer strand portion and a helper strand portion separated by a single-strand break, and the support strand comprises a universal nucleotide;

step (2) comprises cleaving the double-stranded scaffold polynucleotide at a cleavage site, the cleavage site defined by a sequence comprising the universal nucleotide in the support strand, wherein cleavage comprises cleaving the support strand and removing the universal nucleotide from the scaffold polynucleotide to provide a cleaved double-stranded scaffold polynucleotide comprising a support strand and a synthesis strand comprising the primer strand portion;

step (3) comprises extending the terminal end of the primer strand portion of the synthesis strand of the cleaved double-stranded scaffold polynucleotide with a first nucleotide of the predefined sequence by the action of a nucleotide transferase or polymerase enzyme, the first nucleotide comprising a reversible terminator group which prevents further extension by the nucleotide transferase or polymerase enzyme;

step (4) comprises removing the reversible terminator group from the first nucleotide of the predefined sequence;

step (5) comprises ligating a double-stranded ligation polynucleotide to the cleaved double-stranded scaffold polynucleotide, the double-stranded ligation polynucleotide comprising a support strand and a helper strand hybridised thereto and further comprising a complementary ligation end, the ligation end comprising:

(i) in the support strand a universal nucleotide and a partner nucleotide for the first nucleotide of the predefined sequence, wherein the partner nucleotide for the first nucleotide of the predefined sequence overhangs the helper strand; and

(ii) in the helper strand a terminal nucleotide lacking a phosphate group;

wherein upon ligation of the support strands the first nucleotide pairs with the partner nucleotide; and

wherein the method further comprises:

(6) cleaving the double-stranded scaffold polynucleotide at a cleavage site, the site defined by a sequence comprising the universal nucleotide in the support strand, wherein cleavage comprises cleaving the support strand and removing the universal nucleotide from the double-stranded scaffold polynucleotide to provide a cleaved double-stranded scaffold polynucleotide comprising a support strand and a synthesis strand comprising a primer strand portion;

(7) extending the terminal end of the primer strand portion of the synthesis strand of the cleaved double-stranded scaffold polynucleotide with a next nucleotide of the predefined nucleotide sequence by the action of a nucleotide transferase or polymerase enzyme, the next nucleotide comprising a reversible terminator group which prevents further extension by the enzyme;

(8) removing the reversible terminator group from the next nucleotide of the predefined sequence; and

(9) ligating a double-stranded ligation polynucleotide to the cleaved double-stranded scaffold polynucleotide, the double-stranded ligation polynucleotide comprising a support strand and a helper strand hybridised thereto and further comprising a complementary ligation end, the ligation end comprising:

(i) in the support strand a universal nucleotide and a partner nucleotide for the next nucleotide of the predefined sequence, wherein the partner nucleotide for the next nucleotide of the predefined sequence overhangs the helper strand; and

(ii) in the helper strand a terminal nucleotide lacking a phosphate group;

wherein upon ligation of the support strands the next nucleotide of the predefined sequence pairs with the partner nucleotide; and

(10) repeating steps (6) to (9) multiple times to provide the double-stranded polynucleotide having the predefined nucleotide sequence.

3. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide occupies position n in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the first nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle, wherein the nucleotide at position n in the support strand is opposite the terminal nucleotide of the helper strand and is paired therewith;

(b) in step (2), the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein position n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion;

d) in step (6) and in cleavage steps of all subsequent cycles:

(i) the universal nucleotide occupies position n in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the next nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle; and

(ii) the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion; and

(e) step (9) and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the terminal nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+1 in the support strand and is paired with the terminal nucleotide of the helper strand; wherein position n is the nucleotide position which upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide will be opposite the next nucleotide of the predefined sequence incorporated in step (7) of that cycle.

4. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide occupies position n+1 in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the first nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle, wherein the nucleotide at position n in the support strand is opposite the terminal nucleotide of the helper strand and is paired therewith, and wherein n+1 is the next nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(c) in step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the terminal nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+2 in the support strand and is paired with the penultimate nucleotide of the helper strand, wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide in step 5 and position n+2 is the second position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(d) in step (6) and in cleavage steps of all subsequent cycles:

(i) the universal nucleotide occupies position n+1 in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the next nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle, and wherein n+1 is the next nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion; and

(e) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the terminal nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+2 in the support strand and is paired with the penultimate nucleotide of the helper strand; wherein position n is the nucleotide position which upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide will be opposite the next nucleotide of the predefined sequence incorporated in step (7) of that cycle and position n+2 is the second position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion.

5. The method according to claim 2 , wherein:

(b) in step (2), the support strand of the scaffold polynucleotide is cleaved between positions n−1 and n−2, wherein positions n−1 and n−2 are respectively the next and subsequent nucleotide positions in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion;

(c) step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the penultimate nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+1 in the support strand and is paired with the terminal nucleotide of the helper strand, wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide in step 5, and wherein position n+1 is the next nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(d) in step (6) and in cleavage steps of all subsequent cycles:

(ii) the support strand of the scaffold polynucleotide is cleaved between positions n−1 and n−2, wherein positions n−1 and n−2 are respectively the next and subsequent nucleotide positions in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion; and

(e) in step (9) and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the penultimate nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+1 in the support strand and is paired with the terminal nucleotide of the helper strand; wherein position n is the nucleotide position which upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide will be opposite the next nucleotide of the predefined sequence incorporated in step (7) of that cycle, and wherein position n+1 is the next nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion.

6. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide occupies position n+2 in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the first nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle, wherein the nucleotide at position n in the support strand is opposite the terminal nucleotide of the helper strand and is paired therewith, and wherein n+2 is the second nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(c) in step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the terminal nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+3 in the support strand and is paired with the nucleotide which is two positions removed from the terminal nucleotide of the helper strand in the direction distal to the primer strand portion, wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide in step 5 and position n+3 is the third position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(d) in step (6), and in cleavage steps of all subsequent cycles:

(i) the universal nucleotide occupies position n+2 in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the next nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle, and wherein n+2 is the second nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion; and

(ii) the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein position n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion; and

(e) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the terminal nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+3 in the support strand and is paired with the nucleotide which is two positions removed from the terminal nucleotide of the helper strand in the direction distal to the primer strand portion; wherein position n is the nucleotide position which upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide will be opposite the next nucleotide of the predefined sequence incorporated in step (7) of that cycle and position n+3 is the third position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion.

7. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide occupies position n+3 in the support strand of the scaffold polynucleotide, wherein n+3 is the third nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion; and in step (2), the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein position n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion;

(b) in step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the terminal nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+4 in the support strand and is paired with the nucleotide which is 3 positions removed from the terminal nucleotide of the helper strand at the complementary ligation end; wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide in step 5, and wherein position n+4 is position 4 in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(c) in step (6), and in cleavage steps of all subsequent cycles the universal nucleotide occupies position n+3 in the support strand of the scaffold polynucleotide, and the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein position n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion; and

(d) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the terminal nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+4 in the support strand and is paired with the nucleotide which is 2 positions removed from the terminal nucleotide of the helper strand at the complementary ligation end.

8. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide occupies position n+3+x in the support strand of the scaffold polynucleotide, wherein n+3 is the third nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion; and in step (2), the support strand of the scaffold polynucleotide is cleaved between positions n and n−1;

(b) in step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the terminal nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+4+x in the support strand and is paired with the nucleotide which is 3+x positions removed from the terminal nucleotide of the helper strand at the complementary ligation end; wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide in step 5, and wherein position n+4 is position 4 in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(c) in step (6), and in cleavage steps of all subsequent cycles the universal nucleotide occupies position n+3+x in the support strand of the scaffold polynucleotide and the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein position n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion;

(d) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the terminal nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+4+x in the support strand and is paired with the nucleotide which is 2+x positions removed from the terminal nucleotide of the helper strand at the complementary ligation end; and

(e) wherein x is a whole number between 1 to 10 or more, and wherein x is the same whole number in steps (2), (5), (6), and (9).

9. The method according to claim 2 , wherein:

(c) in t step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the penultimate nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+2 in the support strand and is paired with the penultimate nucleotide of the helper strand, wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide, and wherein position n+2 is the second nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(d) in step (6), and in cleavage steps of all subsequent cycles:

(e) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the penultimate nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+2 in the support strand and is paired with the penultimate nucleotide of the helper strand; wherein position n is the nucleotide position which upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide will be opposite the next nucleotide of the predefined sequence incorporated in step (7) of that cycle, and wherein position n+2 is the second nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion.

10. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide instead occupies position n+2 in the support strand of the scaffold polynucleotide, wherein position n is the nucleotide position in the support strand which is opposite the position in the synthesis strand which will be occupied by the first nucleotide of the predefined sequence upon its addition to the terminal end of the primer strand portion in that cycle, wherein the nucleotide at position n in the support strand is opposite the terminal nucleotide of the helper strand and is paired therewith, and wherein n+2 is the second nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion; and in step (2), the support strand of the scaffold polynucleotide is cleaved between positions n and n−1;

(b) in step (5), the complementary ligation end of the ligation polynucleotide is structured such the partner nucleotide for the first nucleotide of the predefined sequence is the terminal nucleotide of the support strand and occupies position n, wherein that the universal nucleotide occupies position n+3 in the support strand and is paired with the nucleotide which is 2 positions removed from the terminal nucleotide of the helper strand at the complementary ligation end; wherein position n is the nucleotide position which will be opposite the first nucleotide of the predefined sequence upon ligation of the ligation polynucleotide to the cleaved scaffold polynucleotide in step (5), and wherein position n+3 is position 3 in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(c) in step (6), and in cleavage steps of all subsequent cycles the universal nucleotide occupies position n+2 in the support strand of the scaffold polynucleotide, and the support strand of the scaffold polynucleotide is cleaved between positions n and n−1, wherein position n−1 is the next nucleotide position in the support strand relative to position n in the direction distal to the helper strand/proximal to the primer strand portion; and

(d) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the next nucleotide of the predefined sequence in that cycle is the terminal nucleotide of the support strand and occupies position n, and the universal nucleotide occupies position n+3 in the support strand and is paired with the nucleotide which is 2 positions removed from the terminal nucleotide of the helper strand at the complementary ligation end.

11. The method according to claim 2 , wherein:

(a) prior to and at step (2), the universal nucleotide instead occupies position n+2+x in the support strand of the scaffold polynucleotide, wherein n+2 is the second nucleotide position in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion; and in step (2), the support strand of the scaffold polynucleotide is cleaved between positions n and n−1;

(b) in step (5), the complementary ligation end of the ligation polynucleotide is structured such that the partner nucleotide for the first nucleotide of the predefined sequence is the terminal nucleotide of the support strand and occupies position n, wherein the universal nucleotide occupies position n+3+x in the support strand and is paired with the nucleotide which is 2+x positions removed from the terminal nucleotide of the helper strand at the complementary ligation end; wherein position n+3 is position 3 in the support strand relative to position n in the direction proximal to the helper strand/distal to the primer strand portion;

(c) in step (6), and in cleavage steps of all subsequent cycles the universal nucleotide occupies position n+2+x in the support strand of the scaffold polynucleotide and the support strand of the scaffold polynucleotide is cleaved between positions n and n−1;

(d) in step (9), and in ligation steps of all subsequent cycles, the complementary ligation end of the ligation polynucleotide is structured such that the universal nucleotide occupies position n+3+x in the support strand and is paired with the nucleotide which is 2+x positions removed from the terminal nucleotide of the helper strand at the complementary ligation end; and

(e) wherein x is a whole number between 1 to 10 or more, and wherein x is the same whole number in steps (2), (5), (6), and (9).

12. The method according to claim 1 , wherein the partner nucleotide which pairs with a nucleotide of the predefined sequence is a nucleotide which is naturally complementary with the nucleotide of the predefined sequence.

13. The method according to claim 2 , wherein:

(a) in any one or more cycles of synthesis, or in all cycles of synthesis, prior to step (2) and/or step (6), the scaffold polynucleotide is provided comprising a synthesis strand and a support strand hybridized thereto, and wherein the synthesis strand is provided without a helper strand; and/or

(b) in any one or more cycles of synthesis, or in all cycles of synthesis, prior to step (2) and/or step (6), the synthesis strand is removed from the scaffold polynucleotide.

14. The method according to claim 1 , wherein step (2) comprises:

(a) a two-step cleavage process comprising: a first step comprising removing the universal nucleotide thus forming an abasic site, and a second step comprising cleaving the support strand at the abasic site; or

(b) a one-step cleavage process comprising removing the universal nucleotide with a cleavage enzyme wherein the enzyme is:

i. Endonuclease III;

ii. Endonuclease VIII;

iii. formamidopirimidine DNA glycosylase (Fpg); or

iv. 8-oxoguanine DNA glycosylase (hOGG1).

15. The method according to claim 1 , wherein step (2) comprises: cleaving the support strand with an enzyme.

16. The method according to claim 2 , wherein in steps (1), (5), and/or (9):

(a) the helper strand and the portion of the support strand hybridized thereto are connected by a hairpin loop; and/or

(b) the synthesis strand comprising the primer strand portion and the portion of the support strand hybridized thereto are connected by a hairpin loop; and/or

(c) wherein at least one of the ligation polynucleotides is provided as a single molecule comprising a hairpin loop connecting the support strand and the helper strand at the end opposite the complementary ligation end; and/or

(d) wherein the ligation polynucleotides of each synthesis cycle are provided as single molecules each comprising a hairpin loop connecting the support strand and the helper strand at the end opposite the complementary ligation end.

17. The method according to claim 1 , wherein the synthesis strand comprising the primer strand portion and the portion of the support strand hybridized thereto are tethered to a common surface.

18. The method according to claim 1 , wherein: (a) synthesis cycles are performed in droplets within a microfluidic system; and/or (b) following synthesis the strands of the double-stranded polynucleotide are separated to provide a single-stranded polynucleotide having a pre-defined sequence; and/or (c) following synthesis the double-stranded polynucleotide or a region thereof is amplified.

19. The method according to claim 14 , the two step cleavage process of (a) comprises:

a first step comprising removing the universal nucleotide with a nucleotide-excising enzyme, thus forming an abasic site; and a second step comprising cleaving the support strand at the abasic site with an enzyme having abasic site lyase activity, wherein the enzyme having abasic site lyase activity is:

i. AP Endonuclease 1;

ii. Endonuclease III (Nth); or

iii. Endonuclease VIII.

20. The method according to claim 15 , wherein:

i. the enzyme cleaves the support strand after the nucleotide which is next to the universal nucleotide, thereby creating an overhanging end in the synthesis strand; and/or

ii. the enzyme is Endonuclease V.

21. The method according to claim 17 , wherein the synthesis strand comprising the primer strand portion and the portion of the support strand hybridized thereto are tethered to a common surface via:

i. one or more covalent bonds;

ii. one or more covalent bonds formed between a functional group on the common surface and a functional group on the scaffold molecule, wherein the functional group on the scaffold molecule is an amine group, a thiol group, a thiophosphate group, or a thioamide group; and/or

iii. one or more covalent bonds formed between a functional group on the common surface and a bromoacetyl group provided on a polyacrylamide surface derived using N-(5-bromoacetamidylpentyl) acrylamide (BRAPA).

Assignments (2)

CHANGE OF NAME Recorded Jan 14, 2022

From: OXFORD NANOPORE TECHNOLOGIES LIMITED

To: OXFORD NANOPORE TECHNOLOGIES PLC

Reel/Frame 058737/0664 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021

From: MILTON, JOHN; NAYYAR, SOBIA; RIEDL, JAN; OGAKI, RYOSUKE

To: OXFORD NANOPORE TECHNOLOGIES LIMITED

Reel/Frame 055930/0124 →

Priority Claims (1)

GB 1808474 · May 23, 2018 · national

Continuity (1)

Related Publication 20210198710A1 · Jul 1, 2021

References Cited (100)

US 5681947A · Bergstrom et al. · 1997 [cited by applicant]

US 8653832B2 · Hadwen et al. · 2014 [cited by applicant]

US 8808989B1 · Efcavitch et al. · 2014 [cited by applicant]

US 8828336B2 · Hadwen et al. · 2014 [cited by applicant]

US 10927394B2 · Milton et al. · 2021 [cited by applicant]

US 11884950B2 · Milton et al. · 2024 [cited by applicant]

US 12037636B2 · Milton et al. · 2024 [cited by applicant]

US 20030082536A1 · Delagrave et al. · 2003 [cited by applicant]

US 20030194736A1 · Bitinaite · 2003 [cited by applicant]

US 20060115850A1 · Schatz · 2006 [cited by applicant]

US 20080044862A1 · Schatz et al. · 2008 [cited by applicant]

US 20110269631A1 · Fu et al. · 2011 [cited by applicant]

US 20130085073A1 · Meuleman et al. · 2013 [cited by applicant]

US 20140197028A1 · Jacobs et al. · 2014 [cited by applicant]

US 20140202863A1 · Hadwen · 2014 [cited by applicant]

US 20140363852A1 · Efcavitch et al. · 2014 [cited by applicant]

US 20160046973A1 · Efcavitch et al. · 2016 [cited by applicant]

US 20160046974A1 · Efcavitch et al. · 2016 [cited by applicant]

US 20160108382A1 · Efcavitch et al. · 2016 [cited by applicant]

US 20160168611A1 · Efcavitch et al. · 2016 [cited by applicant]

US 20170218416A1 · Arlow et al. · 2017 [cited by applicant]

US 20190352687A1 · Milton et al. · 2019 [cited by applicant]

US 20210324436A1 · Milton et al. · 2021 [cited by applicant]

US 20210388432A1 · Milton et al. · 2021 [cited by applicant]

US 20220177938A1 · Milton et al. · 2022 [cited by applicant]

US 20220213537A1 · Milton et al. · 2022 [cited by applicant]

US 20220396818A1 · Milton et al. · 2022 [cited by applicant]

US 20240318219A1 · Milton et al. · 2024 [cited by applicant]

US 20250084468A1 · Milton et al. · 2025 [cited by applicant]

AU 2015248673A1 · 2016 [cited by applicant]

CA 2485218A1 · 2003 [cited by applicant]

CN 1860227A · 2006 [cited by applicant]

CN 101680872A · 2010 [cited by applicant]

CN 103502448A · 2014 [cited by applicant]

CN 104093890A · 2014 [cited by applicant]

EP 1181395B1 · 2006 [cited by applicant]

EP 1314783B1 · 2008 [cited by applicant]

GB 2559117A · 2018 [cited by applicant]

JP 2014504153A · 2014 [cited by applicant]

JP 2020506687A · 2020 [cited by applicant]

JP 2021524246A · 2021 [cited by applicant]

JP 2021529548A · 2021 [cited by applicant]

JP 2021529549A · 2021 [cited by applicant]

WO WO2001088173A2 · 2001 [cited by applicant]

WO WO2003100058A2 · 2003 [cited by applicant]

WO WO2005035757A1 · 2005 [cited by applicant]

WO WO2008128111A1 · 2008 [cited by applicant]

WO WO2010025310A2 · 2010 [cited by applicant]

WO WO2011150168A1 · 2011 [cited by applicant]

WO WO2012078312A2 · 2012 [cited by applicant]

WO WO2013112923A1 · 2013 [cited by applicant]

WO WO2014064444A1 · 2014 [cited by applicant]

WO WO2015055981A2 · 2015 [cited by applicant]

WO WO2015110813A1 · 2015 [cited by applicant]

WO WO2015159023A1 · 2015 [cited by applicant]

WO WO2015176070A1 · 2015 [cited by applicant]

WO WO2016034807A1 · 2016 [cited by applicant]

WO WO2016128731A1 · 2016 [cited by applicant]

WO WO2016139477A1 · 2016 [cited by applicant]

WO WO2017009663A1 · 2017 [cited by applicant]

WO WO2018134616A1 · 2018 [cited by applicant]

WO WO2019140353A1 · 2019 [cited by applicant]

WO WO2019150134A1 · 2019 [cited by applicant]

WO WO2019224544A1 · 2019 [cited by applicant]

WO WO2020016605A1 · 2020 [cited by applicant]

WO WO2020016606A1 · 2020 [cited by applicant]

International Search Report and Written Opinion for Application No. PCT/GB2018/050165, mailed Mar. 20, 2018. [cited by applicant]

International Preliminary Report on Patentability for Application No. PCT/GB2018/050165, mailed Aug. 1, 2019. [cited by applicant]

International Search Report and Written Opinion for Application No. PCT/GB2019/051423, mailed Sep. 20, 2019. [cited by applicant]

International Preliminary Report on Patentability for Application No. PCT/GB2019/051423, mailed Dec. 3, 2020. [cited by applicant]

International Search Report and Written Opinion for Application No. PCT/GB2019/052035, mailed Oct. 11, 2019. [cited by applicant]

International Preliminary Report on Patentability for Application No. PCT/GB2019/052035, mailed Jan. 28, 2021. [cited by applicant]

Berger et al., Universal bases for hybridization, replication and chain termination. Nucleic Acids Res. Aug. 1, 2000;28(15):2911-4. [cited by applicant]

Chou et al., Recent Advances in Applications of Droplet Microfluidics. Micromachines Sep. 2, 2015;6(9):1249-71. https://doi.org/10.3390/mi6091249. [cited by applicant]

David et al., Chemistry of Glycosylases and Endonucleases Involved in Base-Excision Repair. Chem Rev. May 7, 1998;98(3):1221-1262. [cited by applicant]

Deangelis et al., Solid-phase reversible immobilization for the isolation of PCR products. Nucleic Acids Res. Nov. 25, 1995; 23(22): 4742-4743. doi: 10.1093/nar/23.22.4742. [cited by applicant]

Gañán-Calvo et al., Focusing capillary jets close to the continuum limit. Nature Physics. Sep. 2, 2007;3:737-42. https://doi.org/10.1038/nphys710. [cited by applicant]

Kosuri et al., Large-scale de novo DNA synthesis: technologies and applications. Nat Methods. May 2014;11(5):499-507. doi: 10.1038/nmeth.2918. [cited by applicant]

Minhaz Ud-Dean, A theoretical model for template-free synthesis of long DNA sequence. Syst Synth Biol. Dec. 2008;2(3-4):67-73. doi: 10.1007/s11693-009-9023-x. Epub Apr. 3, 2009. [cited by applicant]

Motea et al., Terminal deoxynucleotidyl transferase: the story of a misguided DNA polymerase. Biochim Biophys Acta. May 2010;1804(5):1151-66. doi: 10.1016/j.bbapap.2009.06.030. Epub Jul. 29, 2009. [cited by applicant]

Ponferrada-Marín et al., ROS1 5-methylcytosine DNA glycosylase is a slow-turnover catalyst that initiates DNA demethylation in a distributive fashion. Nucleic Acids Res. Jul. 2009;37(13):4264-74. doi: 10.1093/nar/gkp390… [cited by applicant]

Quan et al., Parallel on-chip gene synthesis and application to optimization of protein expression. Nat Biotechnol. May 2011;29(5):449-52. doi: 10.1038/nbt.1847. Epub Apr. 24, 2011. [cited by applicant]

Ramadan et al., De novo DNA synthesis by human DNA polymerase lambda, DNA polymerase mu and terminal deoxyribonucleotidyl transferase. J Mol Biol. May 28, 2004;339(2):395-404. [cited by applicant]

Roy et al., Synthesis of DNA/RNA and their analogs via phosphoramidite and H-phosphonate chemistries. Molecules. Nov. 18, 2013;18(11):14268-84. doi: 10.3390/molecules181114268. [cited by applicant]

Schweitzer et al., Hydrophobic, Non-Hydrogen-Bonding Bases and Base Pairs in DNA. J Am Chem Soc. Feb. 22, 1995;117(7):1863-1872. doi: 10.1021/ja00112a001. [cited by applicant]

Tannous et al., Role of RNase H1 in DNA repair: removal of single ribonucleotide misincorporated into DNA in collaboration with RNase H2. Scientific Reports. 2015;5(9969). doi: 10.1038/screp09969. 11 pages. [cited by applicant]

Trevino et al., DNA microarrays: a powerful genomic tool for biomedical and clinical research. Mol Med. Sep.-Oct. 2007; 13(9-10): 527-541. EPub Jun. 11, 2007. doi: 10.2119/2006-00107.Trevino. [cited by applicant]

Woodman et al., Archaeal Hel308 domain V couples DNA binding to ATP hydrolysis and positions DNA for unwinding over the helicase ratchet. J Mol Biol. Dec. 14, 2007;374(5):1139-44. Epub Oct. 10, 2007. [cited by applicant]

Wu, Molecular Engineering of Novel Nucleotide Analogues for DNA Sequencing By Synthesis. PhD Thesis. Columbia University. 2008. 231 pages. [cited by applicant]

Search Report for Application No. GB 1913041.8, mailed Feb. 21, 2020. [cited by applicant]

International Search Report and Written Opinion for Application No. PCT/GB2019/052036, mailed Oct. 14, 2019. [cited by applicant]

International Preliminary Report on Patentability for Application No. PCT/GB2019/052036, mailed Jan. 28, 2021. [cited by applicant]

International Search Report and Written Opinion for Application No. PCT/GB2019/052037, mailed Oct. 15, 2019. [cited by applicant]

International Preliminary Report on Patentability for Application No. PCT/GB2019/052037, mailed Jan. 28, 2021. [cited by applicant]

International Search Report and Written Opinion for Application No. PCT/GB2020/052172, mailed Dec. 15, 2020. [cited by applicant]

International Preliminary Report on Patentability for Application No. PCT/GB2020/052172, mailed Mar. 24, 2022. [cited by applicant]

Bauer et al., Comparative analysis of the end-joining activity of several DNA ligases. PLOS One. Dec. 28, 2017;12(12):e0190062. doi: 10.1371/journal.pone.0190062. [cited by applicant]

Tian et al., Template-free, polymerase-free DNA polymerization. Chem Commun (Camb). Jun. 7, 2005;(21):2669-71. doi: 10.1039/b501132a. Epub Apr. 14, 2005. [cited by applicant]

Bentley et al., Accurate whole human genome sequencing using reversible terminator chemistry. Nature. Nov. 6, 2008;456(7218):53-9. doi: 10.1038/nature07517. [cited by applicant]

Chen et al., The history and advances of reversible terminators used in new generations of sequencing technology. Genomics Proteomics Bioinformatics. Feb. 2013;11(1):34-40. doi: 10.1016/j.gpb.2013.01.003. Epub Jan. 23, … [cited by applicant]